**Supplementary Appendix**

**Supplementary Table S1.** Comparison of PD-L1 diagnostic assays for patients with NSCLC

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Test** | **Ventana SP263(1)** | **Dako 22C3 (2)** | **Dako 28-8 (3)** | **Ventana SP142 (4)** |
| **Developed as companion diagnostic assay for:** | Durvalumab (AstraZeneca/ MedImmune) | Pembrolizumab (Merck Sharp & Dohme) | Nivolumab  (Bristol-Myers Squibb) | Atezolizumab  (Genentech) |
| **Instrument** | VENTANA BenchMark ULTRA | Dako Autostainer Link 48 | Dako Autostainer  Link 48 | VENTANA BenchMark ULTRA |
| **PD-L1 antibody** | Clone SP263 (rabbit monoclonal) | Clone 22C3 (mouse monoclonal) | Clone 28-8 (rabbit monoclonal) | Clone SP142 (rabbit monoclonal) |
| **Compartment** | Tumor cell membrane | Tumor cell membrane | Tumor cell membrane | Tumor cells and tumor-infiltrating immune cells |
| **Cut-off(s) for  high PD-L1 expression** | ≥25% of tumor cells(5) | ≥1%; ≥50% of tumor cells(6) | ≥1%; ≥5%; ≥10% of tumor cells (7) | ≥50% of tumor cells  or ≥10% of tumor area with immune cells (if <50% of tumor cells) (8) |
| **Approval status** | CE-IVD  IVD Class I | IVD companion diagnostic | IVD complementary diagnostic | IVD complementary diagnostic |

Abbreviations: CE, European Conformity; IVD, in vitro diagnostic; PD-L1, programmed cell death ligand-1.

**Supplementary Table S2.** Detailed scoring criteria for each assay in the study\*

|  |  |
| --- | --- |
| **Assay** | **Tumour cell scoring (%)** |
| **Ventana SP263** | <1, 1–4, 5–9, ≥10, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 |
| **Dako 22C3** | 0 to 5 in increments of 1%, 10, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 |
| **Dako 28-8** | 0 to 10 in increments of 1%, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 |

**\***Scoring was performed as per manufacturers’ recommendations, but additional granularity was included to provide meaningful data for comparisons.

**Supplementary Table S3.** Demographics of patients who provided study samples

|  |  |
| --- | --- |
| **Parameter** | ***N* = 493** |
| Age range in years, n (%)  ≤60  >60  Unknown | 231 (46.9)  257 (52.1)  5 (1.0) |
| Sex, n (%)  Female  Male | 118 (23.9)  375 (76.1) |
| Ethnicity, n (%)  Caucasian  Asian/Pacific Islander  Unknown | 371 (75.3)  121 (24.5)  1 (0.2) |
| Disease stage (TNM), n (%)  I  II  III  IV  Unknown | 188 (38.1)  191 (38.7)  98 (19.9)  2 (0.4)  14 (2.8) |
| Histology, n (%)  Non-squamous  Squamous  Adenosquamous | 270 (54.8)  210 (42.6)  13 (2.6) |

**Supplementary Table S4.** OPA for pairwise assay comparisons across the full assay range

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Ventana SP263 vs. Dako 28-8** | | | **Dako 22C3 vs. Dako 28-8** | | **Ventana SP263 vs. Dako 22C3** | |
| **Expression cut-off** | | **OPA** | **Lower 95% CI** | **OPA** | **Lower 95% CI** | **OPA** | **Lower 95% CI** |
| ≥1% | 91.7% | | 89.3% | 93.7% | 91.6% | 91.1% | 88.7% |
| ≥5% | 94.1% | | 92.1% | 95.3% | 93.5% | 92.7% | 90.5% |
| ≥10% | 92.9% | | 90.7% | 94.9% | 93.0% | 92.7% | 90.5% |
| ≥20% | 94.5% | | 92.5% | 97.4% | 95.8% | 93.1% | 90.9% |
| ≥25% | 94.9% | | 93.0% | 96.6% | 94.9% | 94.3% | 92.3% |
| ≥30% | 96.3% | | 94.6% | 97.2% | 95.6% | 95.5% | 93.7% |
| ≥40% | 96.8% | | 95.1% | 97.0% | 95.4% | 94.1% | 92.1% |
| ≥50% | 95.9% | | 94.2% | 97.2% | 95.6% | 93.5% | 91.4% |
| ≥60% | 95.7% | | 93.9% | 96.1% | 94.4% | 93.5% | 91.4% |
| ≥70% | 95.5% | | 93.7% | 95.7% | 93.9% | 94.5% | 92.5% |
| ≥80% | 95.1% | | 93.2% | 96.3% | 94.6% | 94.7% | 92.8% |
| ≥90% | 94.9% | | 93.0% | 96.8% | 95.1% | 93.3% | 91.2% |
| 100% | 95.9% | | 94.2% | 97.8% | 96.3% | 94.9% | 93.0% |

Abbreviations: CI, confidence interval; OPA, overall percentage agreement.

**References**

1. Ventana Medical Systems. Ventana PD-L1 (SP263) Assay. Last accessed 10 August 2016. <http://www.ventana.com/product/1815?type=2324>

2. Food and Drug Administration (FDA). Dako PD-L1 IHC 22C3 pharmDx. September 2015. Last accessed 10 August 2016. <http://www.accessdata.fda.gov/cdrh_docs/pdf15/P150013c.pdf>

3. Food and Drug Administration (FDA). Dako PD-L1 IHC 28-8 pharmDx. October 2015. Last accessed 10 August 2016. <http://www.accessdata.fda.gov/cdrh_docs/pdf15/P150025c.pdf>

4. Ventana Medical Systems. VENTANA PD-L1 (SP142) Assay. 21 October 2016. Last accessed 22 November 2016. <http://productlibrary.ventana.com/ventana_portal/OpenOverlayServlet?launchIndex=1&objectId=740-48591016217US>

5. Rizvi NA, Brahmer JR, Ou S-HI, Segal NH, Khleif S, Hwu W-J, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33(15\_Suppl.):8032 (abstr).

6. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.

7. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.

8. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46.